ATE485296T1 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit - Google Patents

(1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit

Info

Publication number: ATE485296T1
Authority: AT; Austria
Prior art keywords: pyridinyl; dichloro; analgesic effectiveness; analgesic; effectiveness
Prior art date: 2003-05-27

Application number

AT04752844T

Other languages

English (en)

Inventor

Michael Buckley

Jianguo Ji

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-27

Filing date

2004-05-20

Publication date

2010-11-15

2004-05-20 Application filed by Abbott Lab filed Critical Abbott Lab

2010-11-15 Application granted granted Critical

2010-11-15 Publication of ATE485296T1 publication Critical patent/ATE485296T1/de

Links

230000000202 analgesic effect Effects 0.000 title 1
MBQYQLWSBRANKQ-IMTBSYHQSA-N (1s,5s)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane Chemical compound N1=C(Cl)C(Cl)=CC(N2C[C@H]3NC[C@H]3C2)=C1 MBQYQLWSBRANKQ-IMTBSYHQSA-N 0.000 abstract 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT04752844T 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit ATE485296T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/445,555 US20040242641A1 (en)	2003-05-27	2003-05-27	(1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
PCT/US2004/015905 WO2004106342A1 (en)	2003-05-27	2004-05-20	(1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent

Publications (1)

Publication Number	Publication Date
ATE485296T1 true ATE485296T1 (de)	2010-11-15

Family

ID=33450880

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04752844T ATE485296T1 (de)	2003-05-27	2004-05-20	(1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit

Country Status (21)

Country	Link
US (1)	US20040242641A1 (de)
EP (1)	EP1626973B1 (de)
JP (1)	JP4716999B2 (de)
KR (2)	KR101238281B1 (de)
CN (1)	CN1826344B (de)
AT (1)	ATE485296T1 (de)
AU (1)	AU2004243270B2 (de)
BR (1)	BRPI0410808A (de)
CA (1)	CA2526530C (de)
CY (1)	CY1111946T1 (de)
DE (1)	DE602004029671D1 (de)
DK (1)	DK1626973T3 (de)
ES (1)	ES2352199T3 (de)
MX (1)	MXPA05012738A (de)
NZ (2)	NZ588123A (de)
PL (1)	PL1626973T3 (de)
PT (1)	PT1626973E (de)
SI (1)	SI1626973T1 (de)
TW (1)	TWI332502B (de)
WO (1)	WO2004106342A1 (de)
ZA (1)	ZA200509601B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7094572B2 (en) *	2003-03-14	2006-08-22	Bristol-Myers Squibb	Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7354937B2 (en) *	2004-05-21	2008-04-08	Abbott Laboratories	(1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20050261348A1 (en) *	2004-05-21	2005-11-24	Buckley Michael J	(1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7351833B2 (en) *	2004-07-23	2008-04-01	Abbott Laboratories	(1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
WO2008028903A2 (en)	2006-09-04	2008-03-13	Neurosearch A/S	Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8222278B2 (en) *	2008-06-03	2012-07-17	Abbott Laboratories	Treatment of attention-deficit/hyperactivity disorder
EP2491031B1 (de)	2009-10-23	2013-08-07	Janssen Pharmaceutica N.V.	Kondensierte heterocyclische verbindungen als orexinrezeptormodulatoren
EP2491034B1 (de) *	2009-10-23	2013-12-18	Janssen Pharmaceutica, N.V.	Kondensierte heterocyclische verbindungen als orexinrezeptormodulatoren
ME03452B (de)	2009-10-23	2020-01-20	Janssen Pharmaceutica Nv	Disubstituierte octahy-dropyrrolo [3,4-c]pyrrole als orexinrezeptormodulatoren
WO2011090669A1 (en) *	2010-01-20	2011-07-28	Abbott Laboratories	Methods for treating pain
WO2012145581A1 (en)	2011-04-20	2012-10-26	Janssen Pharmaceutica Nv	Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
KR20230116948A (ko)	2016-03-10	2023-08-04	얀센 파마슈티카 엔.브이.	오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5478939A (en) *	1994-07-20	1995-12-26	American Cyanamid Company	(R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
EP1147112B1 (de) *	1999-01-29	2003-10-29	Abbott Laboratories	Diazabicyloderivate als nikotin-acetylcholin-rezeptorliganden
EP1175416B1 (de) *	1999-04-26	2003-07-16	Neurosearch A/S	Heteroaryl-diazacycloalkane, ihre herstellung und verwendung
ES2226844T3 (es) *	1999-05-21	2005-04-01	Abbott Laboratories	Aminoazaciclos heterociclicos sustituidos utiles como agentes activos sobre el sistema nervioso central.
MY145722A (en)	2000-04-27	2012-03-30	Abbott Lab	Diazabicyclic central nervous system active agents

2003
- 2003-05-27 US US10/445,555 patent/US20040242641A1/en not_active Abandoned
2004
- 2004-05-20 BR BRPI0410808-6A patent/BRPI0410808A/pt not_active IP Right Cessation
- 2004-05-20 NZ NZ588123A patent/NZ588123A/en not_active IP Right Cessation
- 2004-05-20 ES ES04752844T patent/ES2352199T3/es not_active Expired - Lifetime
- 2004-05-20 PT PT04752844T patent/PT1626973E/pt unknown
- 2004-05-20 PL PL04752844T patent/PL1626973T3/pl unknown
- 2004-05-20 DE DE602004029671T patent/DE602004029671D1/de not_active Expired - Lifetime
- 2004-05-20 WO PCT/US2004/015905 patent/WO2004106342A1/en not_active Ceased
- 2004-05-20 SI SI200431546T patent/SI1626973T1/sl unknown
- 2004-05-20 EP EP04752844A patent/EP1626973B1/de not_active Expired - Lifetime
- 2004-05-20 CA CA2526530A patent/CA2526530C/en not_active Expired - Fee Related
- 2004-05-20 AT AT04752844T patent/ATE485296T1/de active
- 2004-05-20 JP JP2006533261A patent/JP4716999B2/ja not_active Expired - Fee Related
- 2004-05-20 MX MXPA05012738A patent/MXPA05012738A/es active IP Right Grant
- 2004-05-20 NZ NZ543615A patent/NZ543615A/xx not_active IP Right Cessation
- 2004-05-20 CN CN2004800213271A patent/CN1826344B/zh not_active Expired - Fee Related
- 2004-05-20 DK DK04752844.3T patent/DK1626973T3/da active
- 2004-05-20 KR KR1020127001475A patent/KR101238281B1/ko not_active Expired - Fee Related
- 2004-05-20 AU AU2004243270A patent/AU2004243270B2/en not_active Ceased
- 2004-05-20 KR KR1020057022595A patent/KR20060015738A/ko not_active Abandoned
- 2004-05-26 TW TW093114944A patent/TWI332502B/zh not_active IP Right Cessation
2005
- 2005-11-28 ZA ZA200509601A patent/ZA200509601B/en unknown
2011
- 2011-01-11 CY CY20111100032T patent/CY1111946T1/el unknown

Also Published As

Publication number	Publication date
CN1826344B (zh)	2013-03-06
BRPI0410808A (pt)	2006-06-27
JP2007500220A (ja)	2007-01-11
WO2004106342A1 (en)	2004-12-09
SI1626973T1 (sl)	2011-01-31
MXPA05012738A (es)	2006-02-22
NZ543615A (en)	2009-04-30
US20040242641A1 (en)	2004-12-02
DK1626973T3 (da)	2011-01-10
CY1111946T1 (el)	2015-11-04
KR20060015738A (ko)	2006-02-20
EP1626973B1 (de)	2010-10-20
AU2004243270A1 (en)	2004-12-09
KR101238281B1 (ko)	2013-03-04
TW200510420A (en)	2005-03-16
CA2526530A1 (en)	2004-12-09
CA2526530C (en)	2013-01-08
KR20120014235A (ko)	2012-02-16
ZA200509601B (en)	2006-10-25
PL1626973T3 (pl)	2011-04-29
AU2004243270B2 (en)	2009-12-17
TWI332502B (en)	2010-11-01
EP1626973A1 (de)	2006-02-22
PT1626973E (pt)	2010-12-31
CN1826344A (zh)	2006-08-30
NZ588123A (en)	2012-04-27
ES2352199T3 (es)	2011-02-16
JP4716999B2 (ja)	2011-07-06
HK1092135A1 (en)	2007-02-02
DE602004029671D1 (de)	2010-12-02

Legal Events

Date

Code

Title

Description

2011-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1626973

Country of ref document: EP

Publication	Publication Date	Title
CY1111946T1 (el)	2015-11-04	To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας
MY133667A (en)	2007-11-30	Quinazoline ditosylate salt compounds
MXPA05010819A (es)	2006-03-30	Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
MA30340B1 (fr)	2009-04-01	Nouveaux composes
WO2005107726A3 (en)	2006-08-24	Method for the treatment of back pain
AU2003272285A8 (en)	2004-03-29	Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
TR200102021T2 (tr)	2001-12-21	TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
TW200608979A (en)	2006-03-16	Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
NO20035025L (no)	2003-11-12	Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
WO2004110380A3 (en)	2005-03-10	Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2002066500A3 (de)	2003-01-30	ANTAGONISTEN FÜR Α4β7-INTEGRIN
DE602005023467D1 (de)	2010-10-21	(1s,5s)-3-(5,6-dichlorpyridin-3-yl)-3,6-diazabicycloä3.2.0üheptanbenzolsulfonat
WO2005023302A3 (en)	2005-04-28	Anti-cd20 therapy of ocular disorders
SE9802208D0 (sv)	1998-06-22	Novel compounds
WO2005092009A3 (en)	2006-02-09	Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2006074265A3 (en)	2007-06-14	Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
DE60233350D1 (de)	2009-09-24	IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
AU2002332488A8 (en)	2004-02-25	R-bambuterol, its preparation and therapeutic uses
ZA200501288B (en)	2005-09-05	Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
SE9802209D0 (sv)	1998-06-22	Novel compounds
TW200616631A (en)	2006-06-01	(1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
WO2000076500A3 (en)	2001-07-12	Compound for use as a medicament for treatment of disorders involving bronchocontraction
AU2003255843A1 (en)	2004-03-11	1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
MY142646A (en)	2010-12-15	Chemokine receptor antagonists and methods of use therefor
BG105984A (bg)	2002-04-30	Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението